CAR T in Practice: Translating ZUMA-7 Trial Data for Axi-Cel in Second-Line Treatment Decisions

CAR T in Practice: Translating ZUMA-7 Trial Data for Axi-Cel in Second-Line Treatment Decisions

An expert discusses how the ZUMA-7 trial marked a pivotal shift in the treatment of primary refractory diffuse large B-cell lymphoma by demonstrating that second-line CAR T-cell therapy not only improves overall survival compared with standard care but also leads to faster functional recovery, reinforcing the importance of early referral and positioning CAR T as a preferred curative-intent option rather than a last resort.